Objective
Ocular drug development has transformed from niche area to a major field in drug development in which many companies, including European big pharma has entered recently. Ocular drug development is a unique field in terms of drug targets and end-points of activity, local drug administration routes, tissue barriers and pharmacokinetics, drug delivery and formulation challenges and local toxicity issues. These issues are slowing down the development of drugs for the unmet needs in ophthalmology. The main objective of the proposal is to educate experts of preclinical ocular R&D to facilitate the success of European pharmaceutical industry and research community. This objective will be reached by joining forces of the leading European academic and industrial researchers in ophthalmology, materials science and nanomedicine, drug delivery and targeting, and systems pharmacology. We shall educate 15 Early Stage Researchers in a network where they will receive tailored, multi-disciplinary and inter-sectoral education in preclinical ocular drug development. The thesis projects are directed to the drug treatment of retinal diseases, the major challenge in the field. The proposal combines new drug candidates from the experts of ophthalmology, innovative drug delivery technologies from pharmaceutical scientists and companies, and modern in vitro, in silico and in vivo methods from various partners. The thesis projects include secondments in academic and industrial partner laboratories and course programme that encompasses the relevant fields in ocular drug development. Therefore, this proposal presents unique combination of innovation and education in the field with obvious need for such education. The ESRs and other outcomes of this project will greatly benefit the future competitiveness of European science and industry in this field of expanding importance.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesbasic medicinepathology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesclinical medicineophthalmologyretinopathy
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
70211 KUOPIO
Finland
See on map
Participants (8)
72074 Tuebingen
See on map
BT7 1NN Belfast
See on map
67081 Strasbourg
See on map
5612 AE Eindhoven
See on map
35122 Padova
See on map
3584 CS Utrecht
See on map
13288 Marseille
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
EC2Y 5EB London
See on map
Partners (9)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
51373 Leverkusen
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
7522 NB Enschede
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Zürich
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
40 055 Katowice
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
28040 Madrid
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
20520 TURKU
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Gessate
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SW19 7LH London
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
9713 GX Groningen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.